Strides Pharma debuts with stellar ESG rating

IMT News Desk
IMT News Desk
· 2 min read

Receives an ESG score of 76/100 and CSA score of 75/100 in the Corporate Sustainability Assessment (CSA) Annual Review

Strides Pharma Science has received an ESG score of 76/100 and CSA score of 75/100 in the Corporate Sustainability Assessment (CSA) Annual Review for its debut submission. This accomplishment is a significant milestone in our Environmental, Social, and Governance (ESG) journey and further validates our ongoing commitment to sustainability.

With this achievement, Strides has secured a position in the 94th percentile among its peers in the DRG Global Pharmaceuticals industry. On Customer Relations, the Company achieved 100th percentile, showcasing its unwavering commitment to exceptional service, strong customer relationships, and the highest standards of satisfaction and trust.

The Company has demonstrated exceptional performance by achieving an ESG score of 76/100, driven by the Social and Governance Dimensions, which carry the highest weightage, securing the 97th percentile. In the environmental dimension, the company attained a commendable 87th percentile.

Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD and Group CEO, commented, “We are proud to announce that we have received an industry-leading ESG rating from S&P Global on our debut submission. This accomplishment underscores our unwavering commitment to sustainability. It validates our dedication to responsible business practices and reinforces our ongoing efforts to integrate ESG principles across our business operations. As we continue to strengthen and expand our ESG initiatives, we remain focused on creating a lasting, positive impact for all our stakeholders.”

This outstanding performance is underpinned by key material drivers, including Contribution to Societal Healthcare, Human Capital Management, and Corporate Governance, which continue to be pivotal in shaping the company’s sustainability excellence. We remain committed to maintaining and further enhancing our ESG performance, striving to set new benchmarks in sustainability and responsible business practices in the years ahead.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk